(function(){ var content_array=["

关于诺华<\/b><\/p> \n

诺华致力于创想医药未来，改善人们生活质量，延长人类寿命。我们通过在研发方面的技术领先优势和创新的可及性举措，提供能够减轻社会最大疾病负担的高价值药物。在探索新药的过程中，我们不懈创新，研发投入一直处于全球行业先列。诺华在全球拥有来自140多个国家和地区的约106,000名员工，全球近8亿患者受益于诺华产品。如需更多信息，敬请访问诺华全球网站：https:\/\/www.novartis.com<\/a>。<\/span> <\/p> \n

关于诺华中国<\/b><\/p> \n

诺华公司中文名取意"承诺中华"，即通过不断创新的产品和服务，提高中国人民的健康水平和生活质量。自1987年以来，诺华已有近100款创新药物在华获批。诺华在中国的业务包括诺华创新药物（中国）与山德士（中国），并在北京、上海和江苏设立了研发机构。诺华在中国拥有超过8000名员工。如需更多信息，敬请访问诺华中文网站：http:\/\/www.novartis.com.cn<\/a>。<\/p> \n

\n \n \n \n \n \n \n \n \n

[1] 中国心血管健康与疾病报告2021概要[J]. 中国循环杂志, 2022, 37(06): 553-578.<\/span><\/p> <\/td> \n <\/tr> \n

[2] 中国血脂管理指南（2023年）[J]. 中国循环杂志, 2023, 38(03): 237-271.<\/span><\/p> <\/td> \n <\/tr> \n

[3] Raal F, Kallend D, Ray K, et al. Inclisiran for Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020, 382(16): 1507-1530.<\/span><\/p> <\/td> \n <\/tr> \n

[4] Ray K, Wright R, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020, 382(16): 1507-1519.<\/span><\/p> <\/td> \n <\/tr> \n

[5] Ray K, Troquoy R, Visseren F, et al. Efficacy and Safety Of Twice Yearly Subcutaneous lnclisiran In Patients With High Cardiovascular Risk And Elevated Low-density Lipoprotein Cholesterol Up To 4 Years: The ORION-3 Trial. American Heart Association (AHA) Scientific Sessions 2022.November 5-7, 2022. Chicago, IL.<\/span><\/p> <\/td> \n <\/tr> \n

[6] Ray K, Roell P, Visseren F, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL-C (ORION 3): Results from the 4-year open-label extension of the ORION-1 trial. <\/i>Data presented at the American Heart Association (AHA) Scientific Sessions 2022 on November 7.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n

 <\/p>"]; $("#dvExtra").html(content_array[0]);})();